Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
In phase 3 clinical trials, Novo Nordisks semaglutide showed an average weight loss of 10-15% of body weight when the medication was used for 68 weeks
GLP-1s may help with postmenopausal weight gain
Side effects are similar to those experienced with Semaglutide and Tirzepatide: nausea and gastrointestinal complaints are the most common, but only 7% of patients in a study published in The New England Journal of Medicine1 discontinued the medication due to adverse effects
FAQ What does IGF1 LR3 do to the body
Additionally, Novos strategic management of supply chain challenges has helped maintain the consistent availability of WEGOVY and SAXENDA, boosting patient satisfaction and prescribing confidence
